Daclizumab induction therapy in combination with tacrolimus.
Markus
B H
BH
Department for General and Vascular Surgery, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.
Weber
S
S
Allers
C
C
Hauser
I
I
Encke
A
A
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016031:Liver Transplantation / Q000276:immunology*; D008775:Methylprednisolone / Q000008:administration & dosage; D012086:Reoperation; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D016559:Tacrolimus; D008775:Methylprednisolone